JP2017515812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515812A5 JP2017515812A5 JP2016565334A JP2016565334A JP2017515812A5 JP 2017515812 A5 JP2017515812 A5 JP 2017515812A5 JP 2016565334 A JP2016565334 A JP 2016565334A JP 2016565334 A JP2016565334 A JP 2016565334A JP 2017515812 A5 JP2017515812 A5 JP 2017515812A5
- Authority
- JP
- Japan
- Prior art keywords
- aluminum
- pharmaceutical composition
- composition according
- oxyhydroxide
- aluminum salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166388 | 2014-04-29 | ||
| EP14166355.9 | 2014-04-29 | ||
| EP14166388.0 | 2014-04-29 | ||
| EP14166355 | 2014-04-29 | ||
| PCT/EP2015/059341 WO2015165968A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515812A JP2017515812A (ja) | 2017-06-15 |
| JP2017515812A5 true JP2017515812A5 (https=) | 2018-05-31 |
Family
ID=53039897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565334A Pending JP2017515812A (ja) | 2014-04-29 | 2015-04-29 | アルツハイマー病（ａｄ）の処置および予防 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11065273B2 (https=) |
| EP (2) | EP4209222A1 (https=) |
| JP (1) | JP2017515812A (https=) |
| KR (1) | KR102506460B1 (https=) |
| CN (1) | CN106659736A (https=) |
| AU (1) | AU2015254665A1 (https=) |
| CA (1) | CA2946931A1 (https=) |
| DK (1) | DK3137094T3 (https=) |
| FI (1) | FI3137094T3 (https=) |
| PL (1) | PL3137094T3 (https=) |
| PT (1) | PT3137094T (https=) |
| WO (1) | WO2015165968A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3137094T3 (pl) | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
| EP3137097B1 (en) * | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| EP3137093B1 (en) * | 2014-04-29 | 2017-09-13 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| JP4662719B2 (ja) * | 2002-04-19 | 2011-03-30 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | アルツハイマー病の処置のための免疫学的方法および組成物 |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| WO2009105641A2 (en) | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| AT506820B1 (de) | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| AT506819B1 (de) | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| EP2145898A1 (en) * | 2008-07-15 | 2010-01-20 | CHIESI FARMACEUTICI S.p.A. | Anti-amyloid immunogenic compositions, methods and uses |
| BR112012024708A2 (pt) * | 2010-03-29 | 2016-06-07 | Novartis Ag | composição de compostos orgânicos |
| GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| EP3137097B1 (en) | 2014-04-29 | 2023-06-21 | ADvantage Therapeutics, Inc. | Treatment and prevention of alzheimer's disease (ad) |
| EP3137093B1 (en) | 2014-04-29 | 2017-09-13 | Affiris AG | Treatment and prevention of alzheimer's disease (ad) |
| PL3137094T3 (pl) | 2014-04-29 | 2023-03-13 | Advantage Therapeutics, Inc. | Leczenie i profilaktyka choroby alzheimera (ad) |
-
2015
- 2015-04-29 PL PL15720060.1T patent/PL3137094T3/pl unknown
- 2015-04-29 CN CN201580029850.7A patent/CN106659736A/zh active Pending
- 2015-04-29 EP EP22211552.9A patent/EP4209222A1/en active Pending
- 2015-04-29 PT PT157200601T patent/PT3137094T/pt unknown
- 2015-04-29 FI FIEP15720060.1T patent/FI3137094T3/fi active
- 2015-04-29 KR KR1020167033324A patent/KR102506460B1/ko active Active
- 2015-04-29 JP JP2016565334A patent/JP2017515812A/ja active Pending
- 2015-04-29 EP EP15720060.1A patent/EP3137094B1/en active Active
- 2015-04-29 DK DK15720060.1T patent/DK3137094T3/da active
- 2015-04-29 CA CA2946931A patent/CA2946931A1/en not_active Abandoned
- 2015-04-29 US US15/307,246 patent/US11065273B2/en active Active
- 2015-04-29 WO PCT/EP2015/059341 patent/WO2015165968A1/en not_active Ceased
- 2015-04-29 AU AU2015254665A patent/AU2015254665A1/en not_active Abandoned
-
2021
- 2021-07-08 US US17/370,615 patent/US11857568B2/en active Active
-
2023
- 2023-11-20 US US18/514,612 patent/US20240148782A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527402A5 (https=) | ||
| JP2015212268A5 (https=) | ||
| SMP200700047B (it) | Forme di dosaggio di risedronato | |
| RU2018117557A (ru) | Применение долгодействующих пептидов glp-1 | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| JP2013505205A5 (https=) | ||
| JP2012508734A5 (https=) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2017515812A5 (https=) | ||
| Heathcote et al. | LONG TERM (4 YEAR) EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG+) WITH CHRONIC HEPATITIS B (STUDY 103): PRELIMINARY ANALYSIS: 477 | |
| JP2017105859A5 (https=) | ||
| MA42301B1 (fr) | Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone | |
| JP2017514831A5 (https=) | ||
| NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| JP2019531286A5 (https=) | ||
| FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| JP2019515033A5 (https=) | ||
| JP2017516828A5 (https=) | ||
| SI3137093T1 (en) | Treatment and prevention of Alzheimer's disease | |
| JP2017518275A5 (https=) | ||
| JP2015521598A5 (https=) | ||
| JP2017514829A5 (https=) | ||
| JP2017513866A5 (https=) | ||
| UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) |